Navigation Links
Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
Date:7/1/2008

Submission of Five-Day Dosing Regimen sNDA Targeted for Fiscal Year-end

2008

WOODCLIFF LAKE, N.J., July 1, 2008 /PRNewswire/ -- Eisai Corporation of North America today announced the preliminary efficacy data from a trial initiated in 2002 comparing Dacogen(R) (decitabine) to Best Supportive Care (BSC) in elderly patients with myelodysplastic syndromes (MDS). The data did not demonstrate a statistically significant advantage of Dacogen treatment on median overall survival. However, response rates were similar to those observed in other clinical trials of Dacogen in patients with MDS. In the trial, conducted by the European Organisation for the Research and Treatment of Cancer (EORTC), Dacogen was administered on a three-day dosing schedule. In this study, the number of treatment cycles was limited. MDS is a potentially life-threatening group of bone marrow diseases that limit the production of functional blood cells.

Subsequent to database lock and the completion of data analysis, comprehensive results of the study, including secondary efficacy endpoints and safety data, will be presented by EORTC at an upcoming scientific forum.

Current Development

Eisai plans to submit a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration by the end of the fiscal year for a five-day regimen for Dacogen. The sNDA will be based on a North American, multi-center, open-label, single arm Phase II trial (DACO-020) in which patients received Dacogen every day for five days. The regimen was repeated every four weeks with no limit on the number of treatment cycles that patients could receive as long as they received clinical benefit or until their disease progressed. Median survival at the time of data analysis was 19.4 months and the one-year survival rate for patients treated with Dacogen was 66 percent. An overall complete response rate of 32 percent (International Working Group 2006 C
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Eisais Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting
2. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP)
3. New Data Demonstrates 5-FU Personalized Chemotherapy Management (PCM(R)) Assay Provides Similar Performance to More Complicated Liquid Chromatography-Mass Spectrometry (LC-MS/MS)
4. Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma
5. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
6. Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements
7. CNS Response, Inc. Provides Review of Poster Session Delivered at the American Psychiatric Association 161st Annual Meeting
8. Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohns Disease
9. Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients
10. Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone
11. New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...   Assurex Health, a personalized medicine company ... for behavioral health and chronic pain conditions, today ... equity financing from new and existing investors, according ... Chief Executive Officer. The financing will ... Health,s GeneSight ®  products.  GeneSight,s patented ...
(Date:12/24/2014)... Dec. 23, 2014 Tianyin Pharmaceutical Co., ... specializes in patented biopharmaceutical, modernized traditional Chinese medicine ... today announced that the Company achieved the Public ... Practice (GMP) certificate of TPI,s Qionglai Facility (QLF) ... The public notice period is a significant procedure ...
(Date:12/24/2014)... CHAPEL HILL, N.C. , Dec. 23, 2014 /PRNewswire/ ... marketplace success. As the key link between the medical ... will grow even more in the coming years as ... relationships. According to research by benchmarking ... and MSLs can gain an important edge is by ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Role of Medical Science Liaisons Evolving in Medical Device Sector 2
(Date:12/24/2014)... Dr. Vu Ho, a Dallas based ... practice and med-spa with the addition of new Silk ... cosmetic treatments and services. , “Silk Peel is a ... Dr. Ho. “As a result it can address issues ... spots, discolorations or blemishes.” , Similar to microdermabrasion, ...
(Date:12/24/2014)... Wilsonville, Oregon (PRWEB) December 24, 2014 ... Infinity Rehab sat down with Derek Fenwick, PT, ... legislative changes that will stem from the passing of ... 2014 (IMPACT Act). In this taping of the ... amends title XVIII of the Social Security Act to ...
(Date:12/24/2014)... 24, 2014 (HealthDay News) -- A new, injectable weight-loss ... Drug Administration. The agency on Tuesday approved Saxenda ... who are overweight and have at least one weight-related ... diabetes or high cholesterol. Patients taking the drug, ... diet and exercise regularly, the FDA noted. "Obesity ...
(Date:12/24/2014)... Steven Reinberg HealthDay Reporter ... guidelines from the American Diabetes Association (ADA) call for giving ... diabetes to help prevent heart disease. These new standards ... Cardiology and American Heart Association, which also recommend giving low- ... disease, including people with diabetes. "We agree that the ...
(Date:12/24/2014)... 2014 The 2014 Market Research ... and in-depth research report on COC industry. For ... information, including its definition, classification, application, industry chain ... This report also presents product specification, manufacturing process, ... by regions, technology and applications. Analysis also covers ...
Breaking Medicine News(10 mins):Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 3Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 3
... Using a novel imaging technique to study autistic children, ... areas that govern social processing and learning by observation. ... Lindner Center for Autism, North Shore-Long Island Jewish Health ... annual meeting of the Radiological Society of North America ...
... Advanced Laparoscopic Procedures through the Belly Button: Scar-Free ... ... CLEVELAND, Nov. 28 Cleveland Clinic urologists recently,performed a ... pyeloplasty (uretero-pelvic,junction repair), ileal ureter replacement, and psoas hitch uretero-,neocystostomy ...
... Inc., a leading,provider of medical image review services ... million Series B financing led by Siemens Venture,Capital ... Tang Capital Management participated in the financing., ... imaging and clinical,research, and we are delighted to ...
... of Transplantation Winter Symposium Kicks Off March ... ... Organ transplantation is,increasingly being offered to patients with multiple co-morbidities and ... has prompted the increasing use of donors with characteristics,that increase the risk ...
... first comprehensive review of evidence on pneumococcal conjugate vaccination ... the on-line edition of the journal Lancet Infectious Diseases, ... pneumococcal infection by up to 40 fold, that the ... and that the vaccine can protect HIV-infected infants. ...
... in Energy-based Surgical Systems Uses Intelligent Device Management,to ... Technologies, BOULDER, Colo. and REDWOOD CITY, Calif., ... ; BSX: COV), a world leader in advanced,energy-based ... Device Management (IDM), today announced the global launch ...
Cached Medicine News:Health News:Novel imaging technique shows gray matter increase in brains of autistic children 2Health News:World Firsts by Cleveland Clinic Urologists 2Health News:RadPharm Announces $10 million Series B Financing, led by Siemens Venture Capital 2Health News:RadPharm Announces $10 million Series B Financing, led by Siemens Venture Capital 3Health News:AST 'Emergence to Convergence' Highlights the Latest High-Risk Organ Donor and Recipient Issues 2Health News:Pneumococcal conjugate vaccines can improve the lives of HIV-infected children 2Health News:Covidien Launches First-In-Class, Questra-Based Valleylab(TM) Exchange Software Update System 2Health News:Covidien Launches First-In-Class, Questra-Based Valleylab(TM) Exchange Software Update System 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: